Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR
Molecular Oncology · 2025-07 · 19 (7) · 2109-2119
DOI: 10.1002/1878-0261.13787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 04.01.2025. Verfasst von Stavroula Smilkou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Greece. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Neoplastic Cells, Circulating, Circulating Tumor DNA, Mutation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research-Create-Innovate.
Abstract (Originalsprache)
Plasma cell‐free DNA (cfDNA) analysis to track estrogen receptor 1 ( ESR1 ) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breast cancer (MBC). Plasma‐cfDNA is, up to now, the most frequent liquid biopsy analyte used to evaluate ESR1 mutational status. Circulating tumor cell (CTC) enumeration and molecular characterization analysis provides important clinical information in patients with MBC. In this study, we investigated whether analysis of CTCs and circulating tumor DNA (ctDNA) provide similar or complementary information for the analysis of ESR1 mutations. We analyzed both plasma‐cfDNA ( n = 90) and paired CTC‐derived genomic DNA (gDNA; n = 42) from 90 MBC patients for seven ESR1 mutations. Eight out of 90 (8.9%) plasma‐cfDNA samples tested using the ddPLEX Mutation Detection Assay (Bio‐Rad, Hercules, CA, USA), were found positive for one ESR1 mutation, whereas 11/42 (26.2%) CTC‐derived gDNA samples were found positive for at least one ESR1 mutation. Direct comparison of paired samples ( n = 42) revealed that the ESR1 mutation rate was higher in CTC‐derived gDNA (11/42, 26.2%) than in plasma‐cfDNA (6/42, 14.3%) samples. Our results, using this highly sensitive ddPLEX assay, reveal a higher percentage of mutations in CTC‐derived gDNAs than in paired ctDNA in patients with MBC. CTC‐derived gDNA analysis should be further evaluated as an important and complementary tool to ctDNA for identifying patients with ESR1 mutations and for guiding individualized therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Greece.
- Department of Medical Oncology, University General Hospital of Alexandroupolis, Greece.
- Department of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Hygeia Hospital, Athens, Greece.
- Oncology Unit, Metropolitan Hospital, Athens, Greece.
- Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens, Greece.
ORCID-Profile: Stavroula Smilkou, Aliki Ntzifa, Evi Lianidou
Förderung
- Research-Create-Innovate
Zitieren
APA
Smilkou, S., Ntzifa, A., Tserpeli, V., Balgkouranidou, I., Papatheodoridi, A., Razis, E., Linardou, H., Papadimitriou, C., Psyrri, A., Zagouri, F., Kakolyris, S., & Lianidou, E. (2025). Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR. Molecular Oncology, 19(7), 2109-2119. https://doi.org/10.1002/1878-0261.13787
Vancouver
Smilkou S, Ntzifa A, Tserpeli V, Balgkouranidou I, Papatheodoridi A, Razis E, et al. Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR. Molecular Oncology. 2025;19(7):2109-2119. doi:10.1002/1878-0261.13787
BibTeX
@article{Smilkou2025,
author = {Smilkou, Stavroula and Ntzifa, Aliki and Tserpeli, Victoria and Balgkouranidou, Ioanna and Papatheodoridi, Alkistis and Razis, Evangelia and Linardou, Helena and Papadimitriou, Christos and Psyrri, Amanda and Zagouri, Flora and Kakolyris, Stylianos and Lianidou, Evi},
title = {Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {7},
pages = {2109--2119},
doi = {10.1002/1878-0261.13787}
}
EUVIMED